TY - JOUR
T1 - Phosphodiesterase type 9 (PDE9) in the human lower urinary tract
T2 - An immunohistochemical study
AU - Nagasaki, Shuji
AU - Nakano, Youichi
AU - Masuda, Mariko
AU - Ono, Katsuhiko
AU - Miki, Yasuhiro
AU - Shibahara, Yukiko
AU - Sasano, Hironobu
PY - 2012/3
Y1 - 2012/3
N2 - OBJECTIVES To examine the roles of the one of the cyclic guanosine monophosphate (cGMP)-specific phosphodiesterases (PDEs), PDE9, in human lower urinary tract (LUT), we performed immunohistochemistry (IHC) using autopsy specimens. To demonstrate the potential functional differences between PDE5 and PDE9 in human LUT, the localization of PDE5 and PDE9 was also compared using laser-capture microdissection (LCM)/reverse transcriptase-polymerase chain reaction (RT-PCR) method. MATERIALS AND METHODS We immunolocalized PDE9 in human bladder (60 cases) and prostate (40) specimens using IHC. We performed LCM/RT-PCR evaluation in six human bladders to determine the differential expression patterns of PDE5 and PDE9. RESULTS PDE9 immunoreactivity was detected in the bladder urothelium of all the cases and in 85% of the prostatic urethral urothelium. PDE9 immunoreactivity was detected in the perikaryon of the intramural ganglia. LCM/RT-PCR evaluation showed that PDE5 mRNA was exclusively detected in smooth muscle cells but PDE9 mRNA was mainly detected in the urothelium of the human bladder. CONCLUSION PDE9 is widely distributed in the urothelial epithelium of the human LUT and its potential roles may be different from those of PDE5.
AB - OBJECTIVES To examine the roles of the one of the cyclic guanosine monophosphate (cGMP)-specific phosphodiesterases (PDEs), PDE9, in human lower urinary tract (LUT), we performed immunohistochemistry (IHC) using autopsy specimens. To demonstrate the potential functional differences between PDE5 and PDE9 in human LUT, the localization of PDE5 and PDE9 was also compared using laser-capture microdissection (LCM)/reverse transcriptase-polymerase chain reaction (RT-PCR) method. MATERIALS AND METHODS We immunolocalized PDE9 in human bladder (60 cases) and prostate (40) specimens using IHC. We performed LCM/RT-PCR evaluation in six human bladders to determine the differential expression patterns of PDE5 and PDE9. RESULTS PDE9 immunoreactivity was detected in the bladder urothelium of all the cases and in 85% of the prostatic urethral urothelium. PDE9 immunoreactivity was detected in the perikaryon of the intramural ganglia. LCM/RT-PCR evaluation showed that PDE5 mRNA was exclusively detected in smooth muscle cells but PDE9 mRNA was mainly detected in the urothelium of the human bladder. CONCLUSION PDE9 is widely distributed in the urothelial epithelium of the human LUT and its potential roles may be different from those of PDE5.
KW - PDE9A protein
KW - cyclic GMP
KW - human
KW - immunohistochemistry
KW - urinary tract
UR - http://www.scopus.com/inward/record.url?scp=84857648292&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857648292&partnerID=8YFLogxK
U2 - 10.1111/j.1464-410X.2011.10429.x
DO - 10.1111/j.1464-410X.2011.10429.x
M3 - Article
C2 - 21736695
AN - SCOPUS:84857648292
SN - 1464-4096
VL - 109
SP - 934
EP - 940
JO - British Journal of Urology
JF - British Journal of Urology
IS - 6
ER -